LONDON–(BUSINESS WIRE)–#Biotechnology–The global Janus kinase (JAK) inhibitors market is expected to post a CAGR of more than 18% during the period 2019-2023, according to the latest market research report by Technavio.
JAK inhibitors are increasingly being adopted for the treatment of various chronic diseases, including rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis, owing to its high efficacy. Research on the use of JAK inhibitors has shown significant results in the clinical stages, which has created the market potential for the vendors. Vendors in the market are also developing novel drugs to treat GVHD. Thus, the growing applications of JAK inhibitors for the treatment of various chronic conditions will fuel the market growth during the forecast period.
As per Technavio, the special drug designations will have a positive impact on the market and contribute to its growth significantly over the forecast period. This global Janus kinase (JAK) inhibitors market 2019-2023 research report also analyzes other important trends and market drivers that will affect market growth over 2019-2023.
Global Janus Kinase (JAK) Inhibitors Market: Special Drug Designations
Many JAK inhibitors have received designations such as the orphan drug designation from regulatory bodies such as the US FDA and the EMA. The increasing number of special designations for drugs in the pipeline is expected to help the vendors with clinical trials, resulting in the quicker approval of drugs. Hence, special drug designations are expected to fuel the growth of the JAK inhibitors market growth during the forecast period.
“Apart from the special drug designations, other factors such as the rising number of strategic alliances, and increasing research grants will have a significant impact on the growth of the Janus kinase (JAK) inhibitors market value during the forecast period,” says a senior analyst at Technavio.
Global Janus Kinase (JAK) Inhibitors Market: Segmentation Analysis
This market research report segments the global Janus kinase (JAK) inhibitors market worth by application (autoimmune disorders, and oncology) and geographic regions (North America, Europe, Asia, and ROW).
The North America region led the Janus kinase (JAK) inhibitors market in 2018, followed by Europe, Asia, and ROW, respectively. The Janus kinase (JAK) inhibitors market analysis report identifies factors such as the strong prevalence and morbid nature of acute GVHD and the lack of approved therapies for the treatment of blood cancer indications to account for the market dominance of North America during the forecast period.
Looking for more information on this market? Request a free sample report
Technavio’s sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
Market Landscape
- Market ecosystem
- Market characteristics
- Market segmentation analysis
Market Sizing
- Market definition
- Market size and forecast
Five Forces Analysis
Market Segmentation
Geographical Segmentation
- Regional comparison
- Key leading countries
Market Drivers
Market Challenges
Market Trends
Vendor Landscape
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Competitive scenario
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at media@technavio.com.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
www.technavio.com